Literature DB >> 15913488

Clinical trials report. The CAMELOT Study.

John M Flack1.   

Abstract

Year:  2005        PMID： 15913488     DOI： 10.1007/s11906-005-0004-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  14 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Association between cardiovascular outcomes and antihypertensive drug treatment in older women.

Authors:  Sylvia Wassertheil-Smoller; Bruce Psaty; Philip Greenland; Albert Oberman; Theodore Kotchen; Charles Mouton; Henry Black; Aaron Aragaki; Maurizio Trevisan
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

Review 3.  Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence.

Authors:  R Preston Mason
Journal:  Atherosclerosis       Date:  2002-12       Impact factor: 5.162

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation.

Authors:  Valdeci da Cunha; Doris M Tham; Baby Martin-McNulty; Gary Deng; Jerrick J Ho; Dennis W Wilson; John C Rutledge; Ronald Vergona; Mark E Sullivan; Yi-Xin Jim Wang
Journal:  Atherosclerosis       Date:  2005-01       Impact factor: 5.162

6.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.

Authors:  R O Estacio; B W Jeffers; N Gifford; R W Schrier
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

7.  Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension.

Authors:  Jean-Claude Tardif; Anique Ducharme; Holly Yu; Jenifer Wogen; Marie-Claude Guertin
Journal:  Clin Ther       Date:  2004-07       Impact factor: 3.393

8.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

9.  Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial.

Authors:  Hans-Peter Bestehorn; Franz-Josef Neumann; Heinz Joachim Büttner; Peter Betz; Peter Stürzenhofecker; Eberhard von Hodenberg; Antoine Verdun; Laszlo Levai; Jean Pierre Monassier; Helmut Roskamm
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

10.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.